Lung data give welcome boost to Boehringer's Gilotrif
This article was originally published in Scrip
Boehringer Ingelheim's Gilotrif (afatinib) has bested Astellas and Roche's Tarceva (erlotinib) in a Phase III study directly comparing the two therapies in advanced squamous cell carcinoma (SCC) of the lung.
You may also be interested in...
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.